Key Takeaways from the CARTITUDE-1 and KarMMa Studies

EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

Now Viewing

EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies

EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

Video content above is prompted by the following questions:

• Please review data from CARTITUDE-1 that led to the approval of ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM).
  • What are some key takeaways for these data?
• Please review data from KarMMa that led to the approval of ide-cel in R/R MM.
  • What are some key takeaways from these data?